Mary Davis

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.

L. Seymour, F. Shepherd, M. Tonato, 2004, Lung cancer.

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

K. Bélanger, E. Eisenhauer, M. Smylie, 2005, Investigational New Drugs.

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

P. Ellis, P. Ellis, A. Price, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule

K. Bélanger, L. Seymour, B. Zee, 1999 .

Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18

L. Seymour, F. Shepherd, M. Tonato, 2001 .